Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cencora Inc (NY: COR )

245.02 -0.67 (-0.27%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Cencora Inc

< Previous 1 2 3 Next >
Looking Into Cencora's Recent Short Interest
Via Benzinga
McKesson Stock Gets A RS Rating Lift To 75
The Relative Strength (RS) Rating for McKesson stock jumped into a new percentile Wednesday, as it got a lift from 70 to 75. 
Via Investor's Business Daily
Cardinal Health Stock Sees IBD RS Rating Improve To 71
In a welcome move, Cardinal Health stock saw its Relative Strength (RS) Rating rise from 65 to 71 on Friday. 
Via Investor's Business Daily
Deep Dive Into Cencora Stock: Analyst Perspectives (6 Ratings)
Via Benzinga
Trump's Win Sends Indices To Record Highs; Financials, Small Caps Surge, Bitcoin Tops $75,000: What's Driving Markets Wednesday?
An “everything rally” powered Wall Street on Wednesday after the 2024 election results, with Donald Trump emerging as the clear presidential winner. 
Via Benzinga
Topics Government
Exposures Political
If You Invested $100 In This Stock 5 Years Ago, You Would Have $300 Today
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,700 Today
Via Benzinga
Cencora Acquires Retina Care Practice Network For $4.6 Billion, Boosts Dividend On Better Than Expected Q4 Earnings
Cencora will potentially pay up to $500 million in aggregate contingent consideration in fiscal years 2027 and 2028. 
Via Benzinga
Analyst Scoreboard: 6 Ratings For Cencora
Via Benzinga
Here's How Much $1000 Invested In Cencora 5 Years Ago Would Be Worth Today
Via Benzinga
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90% 
Via Benzinga
Here's How Much You Would Have Made Owning Cencora Stock In The Last 5 Years
Via Benzinga
Deep Dive Into Cencora Stock: Analyst Perspectives (6 Ratings)
Via Benzinga
$1000 Invested In Cencora 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Deep Dive Into Cencora Stock: Analyst Perspectives (5 Ratings)
Via Benzinga
Why Walgreens Boots Alliance Fell Another 22% in August
The retail pharmacy giant faces ever-mounting headwinds. 
Via The Motley Fool
Is the Temu Hype Warranted?
School's in and we've also got a look at the challenges teachers face while saving for retirement. 
Via The Motley Fool
Opioid Settlement: Drug Distributors McKesson, Cencora, Cardinal Health To Pay $300M To Health Insurers
Three major U.S. drug distributors, McKesson, Cencora, and Cardinal Health, have agreed to a $300 million settlement over claims by health insurers and benefit plans that they contributed to the opioid... 
Via Benzinga
Is Cash Flow a Problem for Walgreens Boots Alliance?
There are plenty of red flags surrounding the business. 
Via The Motley Fool
Peering Into Cencora's Recent Short Interest
Via Benzinga
Here's How Much You Would Have Made Owning Cencora Stock In The Last 5 Years
Via Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have $300 Today
Via Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today
Via Benzinga
Health Care Giant McKesson Dives Amid Big Revenue Miss
McKesson earnings beat estimates, but the drug and health supplies distribution giant badly missed sales estimates. MCK stock dived. 
Via Investor's Business Daily
Topics Earnings
Exposures Financial
COR Stock Earnings: Cencora Beats EPS, Beats Revenue for Q3 2024
COR stock results show that Cencora beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2024. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
AbbVie Appeals To Supreme Court Over Attorney-Client Privilege In 'Long-Standing' AndroGel Case
AbbVie petitions the U.S. Supreme Court to protect its corporate records, arguing a lower court ruling threatens attorney-client privilege. 
Via Benzinga
The 7 Most Undervalued Dividend Stocks to Buy in July 2024
For nearly 100 years income stocks have outperformed the market and these three undervalued dividend stocks are your best buys this month. 
Via InvestorPlace
A Closer Look at 4 Analyst Recommendations For Cencora
Via Benzinga
3 Dividend Compounding Machines Poised for 30%+ Total Returns by 2026
Savvy investors consider three compounder stocks poised to deliver over 30% total returns and ensure steady income streams. 
Via InvestorPlace
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.